Bluebird’s Zynteglo Shows Long-Term Efficacy And Safety Amid US Commercialization Push

Zynteglo (betibeglogene autotemcel), bluebird bio’s gene therapy for transfusion-dependent beta-thalassemia (TDT), inched closer to proving it is potentially curative with data at the American Society of Hematology meeting showing efficacy was maintained in patients with seven years’ worth of follow-up. That could help bolster the case for the treatment as the company works to commercialize it.

The ASH annual meeting, held 10-13 December in New Orleans, included a poster with long-term outcomes data for Zynteglo from the Phase I/II HGB-204 and HGB-205 and Phase III HGB-207 and HGB-212 studies – patients